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Chronic obstructive pulmonary disease
(COPD) is the second most common cause
of emergency admission to hospital in the
UK and one of the most costly inpatient con-
ditions treated by the National Health
Service (NHS).1 One in eight people over
the age of 35 has undiagnosed COPD and,
in recent years, there have been public
health campaigns to identify those ‘missing
millions’ in the UK.2 COPD is a diagnosis
based on clinical symptoms, conﬁrmed by
the presence of obstructive spirometry3 and
there is unreliable evidence for the initiation
of large scale screening approaches to iden-
tify individuals at high risk. Therefore, a
mechanism by which individuals can easily
be identiﬁed as being high risk, from general
practice (GP) databases, and be invited for
spirometry, has important public health
implications.
Electronic health records (EHR) are an
increasingly popular resource in which to
conduct research. Owing to the large volume
of patients encompassed, they provide tre-
mendous statistical power to answer many
clinical questions. However, the devil is in
the detail, as the outcomes obtained from
this type of research are only as good as the
methods used to identify those outcomes to
begin with. A recent paper by Jones et al4
highlighted the very important issue of
missed opportunities for identifying indivi-
duals with COPD at an earlier point in time
in primary care. However, in analysing these
data, the authors did not appreciate the fact
that Read codes used within GP databases
change over time. Some of the codes in the
code list they used to identify people with
COPD did not exist at the time they attribu-
ted a GP to have missed an opportunity to
make a COPD diagnosis. As a result, the
number of diagnostic opportunities missed
was overestimated.
In this issue, Haroon et al5 have published
a case–control study undertaken between
2000 and 2006 in which they have developed
and validated a clinical risk score for use in
primary care to identify people at risk of
COPD using data from the Clinical Practice
Research Datalink (CPRD). The clinical
score incorporates smoking status, a previous
diagnosis of asthma, lower respiratory tract
infections (LRTI) and salbutamol prescrip-
tions in the previous 3 years. The score devel-
oped, when applied to patients over the age
of 35 years and used at their suggested
threshold of 2.5, would have a positive pre-
dictive value of 22.6%, a negative predictive
value of 97.6% and an overall screening yield
of 3.5% for identifying people with COPD.
In real terms, for every 29 records screened,
5 patients would require a clinical assessment
to identify one patient with COPD.
Development of clinical risk scores is import-
ant for population level screening, and the
authors of this paper should be commended
for their statistical rigour and the clarity of
their methodology. However, there are
several important caveats, which require the
reader to be cautious in interpreting the
results.
First, cases were identiﬁed between 2000
and 2006, spanning the implementation of
the ﬁrst quality and outcomes framework
(QOF) for COPD in 2004,6 from which point
the accuracy of coding associated with a
COPD diagnosis improved signiﬁcantly.
While the authors acknowledge one of the
weaknesses of their paper is not using a vali-
dated COPD codelist, thus bringing the
accuracy of the diagnosis of COPD into ques-
tion, this unfortunately leaves the reader
questioning whether the outcome of this
paper is actually just a score that predicts
which patients will be mislabelled as having
COPD in the future. While validation studies
are laborious, they are crucial in ensuring
accuracy of interrogation of EHR; use of a
validated COPD deﬁnition would have
strengthened this paper.7
Second, smoking is the predominant risk
factor for COPD in the UK. Within EHR,
recording of smoking is not always complete
or accurate, particularly pre 2004. In this
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study, nearly 20% of the cases had never smoked, calling
into question the accuracy of deﬁning the cases.
Likewise, misclassiﬁcation of the controls may also have
occurred, as the controls who smoked and had symp-
toms may well have had COPD and not had spirometry.
How this affects the clinical risk tool will depend on the
extent to which any misclassiﬁcation is differential.
Third, owing to the ﬂuctuating nature of coding, the
lack of longevity of speciﬁc Read codes, the introduction
of new Read codes and new coding systems being intro-
duced (such as SNOMED-CT), tools such as this have a
limited lifetime of usage. Furthermore, with changes in
clinical practice and updates to QOF, this algorithm
would beneﬁt from validation in a more recent data set.
Finally, the number and timing of several of the vari-
ables used in the score are likely to affect accuracy. For
example, a patient’s risk of COPD is likely to be different
if they have had one LRTI in the proceeding 3 years as
opposed to more.
Certainly what this paper does provide is an excellent
preliminary analysis from which future models could be
developed, but this risk score in its current format is by
no means a deﬁnitive tool. Undoubtedly, a validation
tool that could be incorporated into GP software to
identify people at risk of COPD would be extremely
useful.
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